论文部分内容阅读
Journal of Clinical Oncology(《临床肿瘤学杂志》)在线期刊2013年8月26日发表了南京八一医院秦叔逵教授(本期责任副主编)等的一项临床III期研究结果。该研究旨在确定与阿霉素相比,FOLFOX4(氟尿嘧啶、亚叶酸钙及奥沙利铂灌注)姑息化疗方案是否可为晚期肝细胞癌(HCC)患者带来生存获益及疗效。这项在中国大陆、台湾地区、韩国及泰国进行的多中心、开放标签、
Journal of Clinical Oncology Online Journal published a clinical Phase III study on August 26, 2013 by Professor Qin Shuqiu from Nanjing Bayi Hospital (Current Associate Editor in Responsibility). The aim of this study was to determine whether parenteral FOLFOX4 (fluorouracil, leucovorin and oxaliplatin infusion) palliative chemotherapy regimen provides survival benefit and efficacy in patients with advanced hepatocellular carcinoma (HCC) compared with doxorubicin. The multi-center, open-label, multi-center, multi-center, multi-